FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567182431> ?p ?o ?g. }

• W2567182431 abstract "Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients’ and clinicians’ values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying antirheumatic drugs (DMARDs), as well as the roles of nonsteroidal anti-rheumatic drugs and non-pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR. Internal Medicine and Rheumatology, Warsaw, Poland; Peter Balint, MD, PhD: National Institute of Rheumatology and Physiotherapy, 3rd Rheumatology Department, Budapest, Hungary; Kevin Barraclough, FRCP, MRCGP: Hoyland House, Painswick, UK; Lina Bianconi, MD: Bibbiano, Italy; Frank Buttgereit, MD: Charit e University Medicine, Department of Rheumatology, Berlin, Germany; Steven Carsons, MD: Stony Brook University School of Medicine, Division of Rheumatology, Allergy and Immunology, Winthrop-University Hospital Campus, Mineola, New York; Daniel Ching, MBChB, FRCP, FRACP: Timaru Hospital, Department of Rheumatology, Timaru, New Zealand; Maria Cid, MD: University of Barcelona Hospital Clinic, Department of Systemic Autoimmune Diseases, Barcelona, Spain; Andreas Diamantopoulos, MD, PhD: Hospital of Southern Norway Trust, Department of Rheumatology, Kristiansand, Norway; William Docken, MD: Brigham and Women’s Hospital, Division of Rheumatology, Boston, Massachusetts; Christina Duftner, MD, PhD, Michael Schirmer, MD: Medical University of Innsbruck, Department of Internal Medicine—Clinic VI, Innsbruck, Austria; Kate Gilbert, Pamela Hildreth, Jean Miller, Lorna Neill, Jennifer Nott, Hannah Padbury: patient representatives from Polymyalgia Rheumatica and Giant Cell Arteritis UK, London, UK; David Jayne, MD, FRCP: University of Cambridge, Department of Medicine, Cambridge, UK; Manuella Lima, MD: Hospital Universit ario Pedro Ernesto, Department of Rheumatology, Rio de Janeiro, Brazil; Ajesh Maharaj, MBBS: University of Kwa Zulu Natal, Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, Department of Internal Medicine, Durban, South Africa; Christian Mallen, MRCGP, PhD: Keele University, Arthritis Research UK Primary Care Centre, Keele, UK; Victor Martinez-Taboada, MD, PhD: Universidad de Cantabria, Hospital Universitario Marqu es de Valdecilla, Facultad de Medicina, Servicio de Reumatolog ia, Santander, Spain; Mehrdad Maz, MD: University of Kansas Medical Center, Department of Medicine, Division of Allergy, Clinical Immunology, and Rheumatology, Kansas City; Steven Merry, MD: Mayo Clinic, Department of Family Medicine, Rochester, Minnesota; Shunsuke Mori, MD, PhD: NHO Kumamoto Saishunsou National Hospital, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, Kohshi, Kumamoto, Japan; Elisabeth Nordborg, MD: Sahlgren University Hospital, Department of Rheumatology, G€ oteborg, Sweden; Carlo Salvarani, MD: Azienda Ospedaliera-IRCCS di Reggio Emilia, Department of Internal Medicine, Division of Rheumatology, Reggio Emilia, Italy; Wolfgang Schmidt, MD: Immanuel Krankenhaus Berlin and Medical Center for Rheumatology Berlin–Buch, Berlin, Germany; Robert Spiera, MD: Hospital for Special Surgery, Department of Medicine, New York, New York; David Tronnier: patient representative from the Mayo Clinic, Rochester, Minnesota; Alexandre Wagner, MD, PhD: Universidade Federal de S~ao Paulo, Department of Internal Medicine, S~ao Paulo, Brazil; Eric L. Matteson, MD, MPH: Mayo Clinic College of Medicine, Department of Health Sciences Research, Division of Rheumatology, Rochester, Minnesota. Drs. Matteson and Dasgupta contributed equally to this work. Dr. Dejaco has received consulting fees, speaking fees, and/ or honoraria from Bristol-Myers Squibb, Pfizer, AbbVie, MSD, Merck Serono, and Roche, and research funding from Pfizer and MSD. Dr. Mackie has received consulting fees, speaking fees, and/or honoraria from Pfizer, Napp Pharmaceuticals, and AstraZeneca. Dr. Bachta has received consulting fees, speaking fees, and/or honoraria from Medac, Abbott, ENEL-MED, Wyeth, and Lilly, and research funding from Wyeth and Lilly. Dr. Balint has received consulting fees, speaking fees, and/or honoraria from Pfizer, SonoSite, and Abbott, and research funding from Abbott and Bristol-Myers Squibb. Dr. Buttgereit has received consulting fees, speaking fees, and/or honoraria from Merck Serono, Horizon Pharma, and Mundipharma, and research funding from Merck Serono and Horizon Pharma. Dr. Carsons has received consulting fees, speaking fees, and/or honoraria from Centocor. Dr. Cid has received consulting fees, speaking fees, and/or honoraria from Centocor, Roche, and Bristol-Myers Squibb. Dr. Cimmino has received consulting fees, speaking fees, and/or honoraria from Roche, Bristol-Myers Squibb, and Menarini, and research funding from Roche. Dr. Duftner has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers Squibb, Pfizer, AbbVie, MSD, Merck Serono, and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or honoraria from UCB Pharma, Pfizer, Cellerix, and Abbott, and research funding from Roche. Dr. Mori has received research funding from Bristol-Myers Squibb. Dr. Salvarani has received consulting fees, speaking fees, and/or honoraria from Novartis. Dr. Schirmer has received consulting fees, speaking fees, and/or honoraria from Abbott, Pfizer, Amgen, GlaxoSmithKline, and MSD. Dr. Schmidt has received consulting fees, speaking fees, and/or honoraria from Berlin-Chemie, Medac, Pfizer, AbbVie, Roche, Mundipharma, UCB, and MSD, and research funding from Mundipharma, Novartis, MJD Pharmaceutical, Actelion, General Electric, Esadie, and Savient. Dr. Spiera has received research funding from Roche/Genentech. Dr. Matteson has received research funding from Ardea, Sanofi, Centocor/Janssen, Celgene, Amgen, Roche, Genentech, Mesoblast, Novartis, Pfizer, and UCB Pharma. Dr. Dasgupta has received consulting fees, speaking fees, and/or honoraria from Merck and research funding from Roche, Mundipharma, and Servier. Address correspondence to Bhaskar Dasgupta, MD, FRCP, Department of Rheumatology, Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, Essex SS0 0RY, UK. E-mail: Bhaskar.dasgupta@southend.nhs.uk. Submitted for publication February 20, 2015; accepted in revised form July 13, 2015. 2570 DEJACO ET AL" @default.
• W2567182431 created "2017-01-06" @default.
• W2567182431 creator A5000581745 @default.
• W2567182431 creator A5003477314 @default.
• W2567182431 creator A5004355994 @default.
• W2567182431 creator A5005890361 @default.
• W2567182431 creator A5012013248 @default.
• W2567182431 creator A5017632946 @default.
• W2567182431 creator A5025829327 @default.
• W2567182431 creator A5026979766 @default.
• W2567182431 creator A5027298393 @default.
• W2567182431 creator A5028528972 @default.
• W2567182431 creator A5028549127 @default.
• W2567182431 creator A5032713218 @default.
• W2567182431 creator A5035698323 @default.
• W2567182431 creator A5035975113 @default.
• W2567182431 creator A5037221330 @default.
• W2567182431 creator A5041313814 @default.
• W2567182431 creator A5050335866 @default.
• W2567182431 creator A5051334937 @default.
• W2567182431 creator A5052273654 @default.
• W2567182431 creator A5053761141 @default.
• W2567182431 creator A5055089221 @default.
• W2567182431 creator A5055490315 @default.
• W2567182431 creator A5055534615 @default.
• W2567182431 creator A5057669440 @default.
• W2567182431 creator A5058094909 @default.
• W2567182431 creator A5058242702 @default.
• W2567182431 creator A5058462155 @default.
• W2567182431 creator A5058891511 @default.
• W2567182431 creator A5059764745 @default.
• W2567182431 creator A5061301032 @default.
• W2567182431 creator A5062084599 @default.
• W2567182431 creator A5062360747 @default.
• W2567182431 creator A5063925149 @default.
• W2567182431 creator A5066463687 @default.
• W2567182431 creator A5069892526 @default.
• W2567182431 creator A5070674274 @default.
• W2567182431 creator A5074441203 @default.
• W2567182431 creator A5076891691 @default.
• W2567182431 creator A5078987765 @default.
• W2567182431 creator A5080953929 @default.
• W2567182431 creator A5086076722 @default.
• W2567182431 creator A5087393973 @default.
• W2567182431 creator A5089152028 @default.
• W2567182431 creator A5089198595 @default.
• W2567182431 creator A5091070383 @default.
• W2567182431 date "2015-01-01" @default.
• W2567182431 modified "2023-09-24" @default.
• W2567182431 title "2015 Recommendations for the Management of Polymyalgia Rheumatica" @default.
• W2567182431 cites W1479701424 @default.
• W2567182431 cites W1641062785 @default.
• W2567182431 cites W1908060123 @default.
• W2567182431 cites W1967784397 @default.
• W2567182431 cites W1968350578 @default.
• W2567182431 cites W1971672948 @default.
• W2567182431 cites W1977409729 @default.
• W2567182431 cites W1981062313 @default.
• W2567182431 cites W1999151514 @default.
• W2567182431 cites W2008624983 @default.
• W2567182431 cites W2020229760 @default.
• W2567182431 cites W2027084477 @default.
• W2567182431 cites W2028475036 @default.
• W2567182431 cites W2028534155 @default.
• W2567182431 cites W2032686039 @default.
• W2567182431 cites W2032887585 @default.
• W2567182431 cites W2033281654 @default.
• W2567182431 cites W2034248891 @default.
• W2567182431 cites W2047008569 @default.
• W2567182431 cites W2047558890 @default.
• W2567182431 cites W2051461792 @default.
• W2567182431 cites W2052896793 @default.
• W2567182431 cites W2060549798 @default.
• W2567182431 cites W2064651331 @default.
• W2567182431 cites W2065329061 @default.
• W2567182431 cites W2067809930 @default.
• W2567182431 cites W2071326876 @default.
• W2567182431 cites W2071828534 @default.
• W2567182431 cites W2073907836 @default.
• W2567182431 cites W2082973955 @default.
• W2567182431 cites W2084214906 @default.
• W2567182431 cites W2085427691 @default.
• W2567182431 cites W2089514348 @default.
• W2567182431 cites W2090350145 @default.
• W2567182431 cites W2092301227 @default.
• W2567182431 cites W2093556378 @default.
• W2567182431 cites W2099866582 @default.
• W2567182431 cites W2100651899 @default.
• W2567182431 cites W2101005100 @default.
• W2567182431 cites W2106612878 @default.
• W2567182431 cites W2111465526 @default.
• W2567182431 cites W2120393706 @default.
• W2567182431 cites W2122814783 @default.
• W2567182431 cites W2124215468 @default.
• W2567182431 cites W2126269417 @default.
• W2567182431 cites W2128230480 @default.
• W2567182431 cites W2128783050 @default.
• W2567182431 cites W2135400982 @default.
• W2567182431 cites W2136403658 @default.
• W2567182431 cites W2138923030 @default.

• next